Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced-intensity conditioning

British Journal of Haematology

Volumn 121, Issue 3, 2003, Pages 411-418

  Einsele, Hermann ^a,c   Schäfer, Hans Jörg ^a   Hebart, Holger ^a   Bader, Peter ^a   Meisner, Christoph ^a   Plasswilm, Ludwig ^a   Liebisch, Peter ^b   Bamberg, Michael ^a   Faul, Christoph ^a   Kanz, Lothar ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c NONE   (Germany)

Author keywords

Long term follow up; Multiple myeloma; Reduced conditioning; Unrelated donor

Indexed keywords

BENDAMUSTINE; BUSULFAN; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DEXAMETHASONE; EPIRUBICIN; ETOPOSIDE; HLA ANTIGEN; IDARUBICIN; IFOSFAMIDE; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; THYMOCYTE ANTIBODY; VINCRISTINE;

ADULT; AGED; ALLOGRAFT; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONDITIONING; DISEASE ASSOCIATION; DISEASE COURSE; DONOR; FEMALE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; LONG TERM CARE; MALE; MORTALITY; MULTIPLE MYELOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; REMISSION; SALVAGE THERAPY; SERODIAGNOSIS; SIBLING; STEM CELL TRANSPLANTATION;

ACUTE DISEASE; ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; CHRONIC DISEASE; CYCLOSPORINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MULTIPLE MYELOMA; MYCOPHENOLIC ACID; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 0038015884     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2003.04299.x     Document Type: Article

References (29)

1. Attal, M., Harousseau, J.L., Stoppa, A.M., Sotto, J.J., Fuzibet, J.G., Rossi, I.F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., Payen, C. & Bataille, R. (1996) A prospective, randomised trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. New England Journal of Medicine, 335, 91-97.
2. Bader, P., Beck, J., Frey, A., Schlegel, P.G., Hebarth, H., Handgretinger, R., Einsele, H., Niemeyer, C., Benda, N., Faul, C., Kanz, L., Niethammer, D. & Klingebiel, T. (1998) Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows prediction of relapse after allogeneic BMT. Bone Marrow Transplantation, 21, 487-495.
3. Badros, A., Barlogie, B., Morris, C., Desikan, R., Martin, S.R., Munshi, N., Zangari, M., Mehta, J., Toor, A., Cottler-Fox, M., Fassas, A., Anaissie, E., Schichman, S., Tricot, G. & Aniassie, E. (2001) High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a non-myeloablative conditioning regimen and donor lymphocyte infusion. Blood, 97, 2574-2579.
4. Barlogie, B., Hall, R., Zander, A., Dicke, K. & Alexanian, R. (1986) High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood, 67, 1298-1301.
5. Barlogie, B., Jagannath, S., Vesole, D.H., Naucke, S., Cheson, B., Mattox, S., Bracy, D., Salmon, S., Jacobson, J., Crowley, J. & Tricot, G. (1997) Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood, 89, 789-793.
6. Bearman, S.I., Appelbaum, F.R., Back, A., Petersen, F.B., Buckner, C.D., Sullivan, K.M., Schoch, H.G., Fisher, L.D. & Thomas, E.D. (1989) Regimen-related toxicity and early posttransplant survival in patients undergoing marrow transplantation for lymphoma. Journal of Clinical Oncology, 7, 1288-1294.
7. Bensinger, W.I., Buckner, C.D., Anasetti, C., Clift, R., Storb, R., Barnett, T., Chauncey, T., Shulman, H. & Appelbaum, F.R. (1996) Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors and outcome. Blood, 88, 2787-2793.
8. Blade, J., Samson, D., Reece, D., Apperley, J., Bjorkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S. & Vesole, D. (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. British Journal of Haematology, 102, 1115-1123.
9. Boccadoro, M. & Pileri, A. (1997) Diagnosis, prognosis, and standard treatment of multiple myeloma. Hematological and Oncological Clinics of North America, 11, 111-131.
10. Chakrabarti, S., Mackinnon, S., Chopra, R., Kottaridis, P.D., Peggs, K., O'Gorman, P., Chakraverty, R., Marshall, T., Osman, H., Mahendra, P., Craddock, C., Waldmann, H., Hale, G., Fegan, C.D., Yong, K., Goldstone, A.H., Linch, D.C. & Milligan, D.W. (2002) High incidence of cytomegalovirus infection after non-myeloablative stem cell transplantation: potential role of Campath1H in delaying immune reconstitution. Blood, 99, 4357-4363.
11. Chakraverty, R., Peggs, K., Chopra, R., Milligan, D.W., Kottaridis, P.D., Verfuerth, S., Geary, J., Thuraisundaram, D., Branson, K., Chakrabarti, S., Mahendra, P., Craddock, C., Parker, A., Hunter, A., Hale, G., Waldmann, H., Williams, C.D., Yong, K., Linch, D.C., Goldstone, A.H. & Mackinnon, S. (2002) Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood, 99, 1071-1078.
12. Corradini, P., Voena, C., Tarella, C., Astolfi, M., Ladetto, M., Palumbo, A., Van Lint, M.T., Bacigalupo, A., Santoro, A., Musso, M., Majolino, I., Boccadoro, M. & Pileri, A. (1999) Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. Journal of Clinical Oncology, 17, 208-215.
13. Desikan, R., Barlogie, B., Sawyer, J., Ayers, D., Tricot, G., Badros, A., Zangari, M., Munshi, N.C., Anaissie, E., Spoon, D., Siegel, D., Jagannath, S., Vesole, D., Epstein, J., Shaughnessy, J., Fassas, A., Lim, S., Roberson, P. & Crowley, J. (2000) Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood, 95, 4008-4010.
14. Einsele, H., Ehninger, G., Hebart, H., Wittkowski, K.M., Schuler, U., Jahn, G., Mackes, P., Herter, M., Klingebiel, T., Loffler, J., Wagner, S. & Müller, C.A. (1995) Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood, 86, 2815-2820.
15. Einsele, H., Hebart, H., Kauffmann-Schneider, C., Sinzger, C., Jahn, G., Bader, P., Klingebiel, T., Dietz, K., Löffler, J., Bokemeyer, C., Müller, C.A. & Kanz, L. (2000) Risk factors for treatment failures in patients receiving PCR-based preemptive antiviral therapy for CMV-infection. Bone Marrow Transplantation, 25, 757-763.
16. Gahrton, G., Tura, S., Ljungman, P., Belanger, C., Brandt, L., Cavo, M., Facon, T., Granena, A., Gore, M., Gratwohl, A., Löwenberg, B., Nikoskelainen, J., Reiffers, J.J., Samson, D., Verdonck, L. & Volin, L. (1991) Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. New England Journal of Medicine, 325, 1267-1273.
17. Giralt, S., Thall, P.F., Khouri, I., Wang, X., Braunschweig, I., Ippolitti, C., Claxton, D., Donato, M., Bruton, J., Cohen, A., Davis, M., Andersson, B.S., Anderlini, P., Gajewski, J., Kornblau, S., Andreeff, M., Przepiorka, D., Ueno, N.T., Molldrem, J. & Champlin, R. (2001) Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood, 97, 631-637.
18. Khouri, I.F., Saliba, R.M., Giralt, S.A., Lee, M.S., Okoroji, G.J., Hagemeister, F.B., Korbling, M., Younes, A., Ippoliti, C., Gajewski, J.L., McLaughlin, P., Anderlini, P., Donato, M.L., Cabanillas, F.F. & Champlin, R.E. (2001) Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease. and treatment-related mortality. Blood, 98, 3595-3599.
19. Kottaridis, P.D., Milligan, D.W., Chopra, R., Chakraverty, R.K., Chakrabarti, S., Robinson, S., Peggs, K., Verfuerth, S., Pettengell, R., Marsh, J.C., Schey, S., Mahendra, P., Morgan, G.J., Hale, G., Waldmann, H., Ruiz de Elvira, M.C., Williams, C.D., Devereux, S., Linch, D.C., Goldstone, A.H. & MacKinnon, S. (2000) In vivo CAMPATH1H prevents graft-versus-host disease following non-myeloablative stem cell transplantation. Blood, 96, 2419-2425.
20. Kröger, N., Schwerdtfeger, R., Kiehl, M., Sayer, H.G., Renges, H., Zabelina, T., Fehse, B., Togel, F., Wittkowsky, G., Kuse, R. & Zander, A.R. (2002) Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood, 100, 755-760.
21. Kulkarni, S., Powles, R.L., Treleaven, J.G., Singhal, S., Saso, R., Horton, C., Killick, S., Tait, D., Ramiah, V. & Mehta, J. (1999) Impact of previous high-close therapy on outcome after allografting for multiple myeloma. Bone Marrow Transplantation, 23, 675-680.
22. McElwain, T.J. & Powles, R.J. (1983) High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet, 2, 822-824.
23. McSweeney, P.A., Niederwieser, D., Shizuru, J.A., Sandmaier, B.M., Molina, A.J., Maloney, D.G., Chauncey, T.R., Gooley, T.A., Hegenbart, U., Nash, R.A., Radich, J., Wagner, J.L., Minor, S., Appelbaum, F.R., Bensinger, W.I., Bryant, E., Flowers, M.E., Georges, G.E., Grumet, F.C., Kiem, H.P., Torok-Storb, B., Yu, C., Blume, K.G. & Storb, R.F. (2001) Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood, 97, 3390-3400.
24. Maloney, D.E., Sahebi, F. & Stocker-Goldstein, K.E. (2001) Combining an allogeneic graft-versus-myeloma effect with high-dose autologous stem cell rescue in the treatment of multiple myeloma. Blood, 98, 434a.
25. Michallet, M., Bilger, K., Garban, F., Attal, M., Huyn, A., Blaise, D., Milpied, N., Moreau, P., Bordigoni, P., Kuentz, M., Sadoun, A., Cahn, J.Y., Socie, G., Thomas, X., Arnaud, P., Raus, N., Lheritier, V., Pigneux, A. & Boiron, J.M. (2001) Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens: impact of pretransplantation and posttransplantation factors on outcome. Journal of Clinical Oncology, 19, 3340-3349.
26. Przepiorka, D., Weisdorf, D., Martin, P., Klingemann, H.G., Beatty, P., Hows, J. & Thomas, E.D. (1995) 1994 consensus conference on acute GVHD grading. Bone Marrow Transplantation, 15, 825-828.
27. Slavin, S., Nagler, A., Naparstek, E., Kapelushnik, Y., Aker, M., Cividalli, G., Varadi, G., Kirschbaum, M., Ackerstein, A., Samuel, S., Amar, A., Brautbar, C., Ben-Tal, O., Eldor, A. & Or, R. (1998) Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic disease. Blood, 91, 756-763.
28. Sullivan, K.M., Agura, E., Anasetti, C., Appelbaum, F., Badger, C., Bearman, S., Erickson, K., Flowers, M., Hansen, J. & Loughran, T. (1991) Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Seminars in Hematology, 28, 250-259.
29. Tricot, G., Vesole, D.H., Jagannath, S., Hilton, J., Munshi, N. & Barlogie, B. (1996) Graft-versus-myeloma effect: proof of principle. Blood, 87, 1196-1198.